Invention Grant
- Patent Title: Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists
-
Application No.: US16260984Application Date: 2019-01-29
-
Publication No.: US10696656B2Publication Date: 2020-06-30
- Inventor: Robert Murray McKinnell
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agent Jeffrey A. Hagenah; Florence Jovenic
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D405/14 ; C07D409/14 ; C07D413/14 ; C07D417/14 ; G01N33/50

Abstract:
The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
Public/Granted literature
- US20190152951A1 BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS Public/Granted day:2019-05-23
Information query